Follow
Michael Kinch
Title
Cited by
Cited by
Year
Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
R Khosravi-Far, PA Solski, GJ Clark, MS Kinch, CJ Der
Molecular and cellular biology, 1995
9121995
Integrin-mediated cell adhesion activates mitogen-activated protein kinases.
Q Chen, MS Kinch, TH Lin, K Burridge, RL Juliano
Journal of Biological Chemistry 269 (43), 26602-26605, 1994
8751994
An analysis of FDA-approved drugs: natural products and their derivatives
E Patridge, P Gareiss, MS Kinch, D Hoyer
Drug discovery today 21 (2), 204-207, 2016
8502016
Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation
H Miao, E Burnett, M Kinch, E Simon, B Wang
Nature cell biology 2 (2), 62-69, 2000
6762000
EphA2 overexpression causes tumorigenesis of mammary epithelial cells
DP Zelinski, ND Zantek, JC Stewart, AR Irizarry, MS Kinch
Cancer research 61 (5), 2301-2306, 2001
6092001
Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia.
MS Kinch, GJ Clark, CJ Der, K Burridge
The Journal of cell biology 130 (2), 461-471, 1995
3991995
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2)
AR Hess, EA Seftor, LMG Gardner, K Carles-Kinch, GB Schneider, ...
Cancer research 61 (8), 3250-3255, 2001
3732001
E-cadherin regulates the function of the EphA2 receptor tyrosine kinase
ND Zantek, M Azimi, M Fedor-Chaiken, B Wang, R Brackenbury, ...
3711999
Overexpression of the EphA2 tyrosine kinase in prostate cancer
J Walker‐Daniels, K Coffman, M Azimi, JS Rhim, DG Bostwick, P Snyder, ...
The Prostate 41 (4), 275-280, 1999
3321999
Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival
MS Kinch, MB Moore, DH Harpole Jr
Clinical cancer research 9 (2), 613-618, 2003
3082003
Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior
K Carles-Kinch, KE Kilpatrick, JC Stewart, MS Kinch
Cancer research 62 (10), 2840-2847, 2002
2992002
EphA2 expression is associated with aggressive features in ovarian carcinoma
PH Thaker, M Deavers, J Celestino, A Thornton, MS Fletcher, CN Landen, ...
Clinical Cancer Research 10 (15), 5145-5150, 2004
2882004
An overview of FDA-approved new molecular entities: 1827–2013
MS Kinch, A Haynesworth, SL Kinch, D Hoyer
Drug discovery today 19 (8), 1033-1039, 2014
2682014
VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry
AR Hess, EA Seftor, LM Gruman, MS Kinch, REB Seftor, MJC Hendrix
Cancer biology & therapy 5 (2), 228-233, 2006
2412006
The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation
GJ Clark, MS Kinch, K Rogers-Graham, SM Sebti, AD Hamilton, CJ Der
Journal of Biological Chemistry 272 (16), 10608-10615, 1997
2311997
An overview of FDA-approved biologics medicines
MS Kinch
Drug discovery today 20 (4), 393-398, 2015
2292015
Differential regulation of EphA2 in normal and malignant cells
J Walker-Daniels, AR Hess, MJC Hendrix, MS Kinch
The American journal of pathology 162 (4), 1037-1042, 2003
2222003
c-Cbl-dependent EphA2 protein degradation is induced by ligand binding
J Walker-Daniels, DJ Riese, MS Kinch
Molecular Cancer Research 1 (1), 79-87, 2002
2092002
Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation
KD Kikawa, DR Vidale, RL Van Etten, MS Kinch
Journal of Biological Chemistry 277 (42), 39274-39279, 2002
2082002
Dynamic interaction of PTPμ with multiple cadherins in vivo
SM Brady-Kalnay, T Mourton, JP Nixon, GE Pietz, M Kinch, H Chen, ...
The Journal of cell biology 141 (1), 287-296, 1998
2041998
The system can't perform the operation now. Try again later.
Articles 1–20